Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has announced the publication 1 in the Journal of Clinical Pathology of a study conducted in collaboration with the Memorial ...

CML is traditionally regarded as a paradigm of precision medicine, under several points of view: 1) it is the first human malignancy whose molecular pathogenesis was unravelled, well before the advent ...